Genmab — Juni 2019

[Sukkeralf]

If I remember correctly Jans first thoughts of new INDs for 2019 was 3-5 and recently it was 3 (and we know them all) but maybe HexaCD38 could have been close so I hope it will be a 2020 IND

[lahn1]

@09:28 yes I see that now. It stille feels early to do this deal, hence the "pure milestone
payement"

[Sukkeralf]

But the deal need to be in place for Genmab to do the costly preclinical work

[lahn1]

yes nice to have a buyer on hand, maybe not as bad a deal as it seemed at first glance

[nohope]

I´ll welcome almost any kind of deals, also, this deal, but it does seem rather far away from what Jan has been talking about. This is a techdeal with a product, this should have been paid upfront and/or on 50/50 basis. But any hole in the no-deal-wall is welcome to me.

[E_L]

I am actually very excited about this deal- Dara is the backbone of this company and Genmab is looking to strengthen and extend that backbone. Extremely important and a sign of mature management with a long term view imo. I really like Sukkeralf's term 'life cycle management' in this respect.

[E_L]

@nohope 09:21 is my answer to that.

[nohope]

Well, you could also say, this emphasasi that GEN is a one-trick pony - Darapony.

[E_L]

even if that would be right; i would rather have a strong pony that lives longer

[nohope]

Ok, I see. Too bad, but still better than the Theresa May scenario

[nohope]

Ponies forever

[Solsen]

To me the agreement is still like Genmab asking Janssens for a deal - not a move from Janssens.

[Solsen]

Perhaps its foresight ?

[Sukkeralf]

when sc dosing of CD38 it should be secured until 2033-35...........a with all the alternatives Janssen is doing right now I agree with Solsen that Genmab has pushed this foreward and Janssen at last agree to "show us what it can do"

[Sukkeralf]

But a nice deal to get in place before a DR5/DR5 deal and to get HexaBody and perhaps HexElect in the spotlight

[troldmanden]

mindes ikke lige at have set en sådan struktureret deal før. Uden noget i upfront

[troldmanden]

POC kan være defineret lidt forskelligt. Men cost bør ikke opverstige 200 mio, og det over de næste 3-4 år. Så det beløb betyder i sig selv ikke noget for genmab. De har også sagt det ikke ændre på forventningerne

[troldmanden]

det er gratis for jansen at lave denne aftale, og de sikre sig endda at Genmab ikke må sætte den op som direkte konkurrent til dara, såfremt jannsen skulle undlade at udnytte optionen

[troldmanden]

Should Janssen not exercise its option, the terms of the agreement allow Genmab to continue to develop and commercialize HexaBody-CD38 for DARZALEX-resistant patients, and in all other indications except those multiple myeloma or amyloidosis indications where DARZALEX is either approved or is being actively developed.

[gentogen]

Ja, men det er vel en OK pointe, at de i givet fald gerne må i Dara-resistente. Det er svært at forestille sig JNJ ikke slå til, hvis det er bedre end Dara...